{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:44:01Z","timestamp":1791420241443,"version":"4.3.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3440-0","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T10:57:26Z","timestamp":1498820246000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole"],"prefix":"10.1186","volume":"17","author":[{"given":"Angela","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Della Pepa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Migali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"key":"3440_CR1","volume-title":"2012: estimated cancer incidence, mortality and prevalence worldwide in 2012","author":"GLOBOCAN","year":"2012","unstructured":"GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012. \nhttp:\/\/globocan.iarc.fr\/Pages\/fact_sheets_population.aspx\n\n (accessed 30 April 2017)."},{"key":"3440_CR2","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1158\/1078-0432.CCR-06-2878","volume":"13","author":"JF Smyth","year":"2007","unstructured":"Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams ARW, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res. 2007;13:3617\u201322. doi:\n10.1158\/1078-0432.CCR-06-2878\n\n.","journal-title":"Clin Cancer Res"},{"key":"3440_CR3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","volume":"14","author":"W Sieh","year":"2013","unstructured":"Sieh W, K\u00f6bel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol. 2013;14:853\u201362.","journal-title":"Lancet Oncol"},{"key":"3440_CR4","first-page":"1051","volume":"18","author":"E H\u00f8gdall","year":"2007","unstructured":"H\u00f8gdall E, Christensen L, H\u00f8gdall C, Blaakaer J, Gayther S, Jacobs I, et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the \u2018MALOVA\u2019 ovarian cancer study. Oncol Rep. 2007;18:1051\u20139.","journal-title":"Oncol Rep"},{"key":"3440_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s12253-010-9340-0","volume":"17","author":"A Halon","year":"2011","unstructured":"Halon A, Materna V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P, et al. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res. 2011;17:511\u20138. doi:\n10.1007\/s12253-010-9340-0\n\n.","journal-title":"Pathol Oncol Res"},{"key":"3440_CR6","first-page":"126","volume":"29","author":"J Geisler","year":"2008","unstructured":"Geisler J, Buller E, Manahan K. Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary. Eur J Gynaecol Oncol. 2008;29:126\u20138.","journal-title":"Eur J Gynaecol Oncol"},{"key":"3440_CR7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/bjc.1990.263","volume":"62","author":"S Langdon","year":"1990","unstructured":"Langdon S, Hawkes M, Lawrie S, Hawkins R, Tesdale A, Crew A, et al. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer. 1990;62:213\u20136.","journal-title":"Br J Cancer"},{"key":"3440_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1677\/erc.1.01039","volume":"12","author":"AJ O\u2019Donnell","year":"2005","unstructured":"O\u2019Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer. 2005;12:851\u201366. doi:\n10.1677\/erc.1.01039\n\n.","journal-title":"Endocr Relat Cancer"},{"key":"3440_CR9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0959-8049(94)90545-2","volume":"30A","author":"S Langdon","year":"1994","unstructured":"Langdon S, Crew A, Ritchie A, Muir M, Wakeling A, Smyth J, et al. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. Eur J Cancer. 1994;30A:682\u20136.","journal-title":"Eur J Cancer"},{"key":"3440_CR10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0090-8258(87)90294-0","volume":"27","author":"S a Weiner","year":"1987","unstructured":"Weiner S a, Alberts DS, Surwit E a, Davis J, Grosso D. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol. 1987;27:208\u201313.","journal-title":"Gynecol Oncol"},{"key":"3440_CR11","first-page":"583","volume":"59","author":"PE Schwartz","year":"1982","unstructured":"Schwartz PE, Keating G, MacLusky N, Naftolin F, Eisenfeld A. Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol. 1982;59:583\u20138.","journal-title":"Obstet Gynecol"},{"key":"3440_CR12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O","volume":"68","author":"K Hatch","year":"1991","unstructured":"Hatch K, Beecham J, Blessing J, Creasman W. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second-line therapy in 105 patients. Cancer. 1991;68:269\u201371.","journal-title":"Cancer"},{"key":"3440_CR13","doi-asserted-by":"crossref","unstructured":"Williams C, Simera I, Bryant A. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2010:CD001034.","DOI":"10.1002\/14651858.CD001034.pub2"},{"key":"3440_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ygyno.2008.03.014","volume":"110","author":"PT Ramirez","year":"2008","unstructured":"Ramirez PT, Schmeler KM, Milam MR, Slomovitz BM, Smith JA, Kavanagh JJ, et al. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol. 2008;110:56\u20139. doi:\n10.1016\/j.ygyno.2008.03.014\n\n.","journal-title":"Gynecol Oncol"},{"key":"3440_CR15","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/1078-0432.CCR-06-2878","volume":"13","author":"JF Smyth","year":"2007","unstructured":"Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams ARW, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res. 2007;13:3617\u201322.","journal-title":"Clin Cancer Res"},{"key":"3440_CR16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000077436","volume":"66","author":"CA Papadimitriou","year":"2004","unstructured":"Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer: long-term results of a phase II study. Oncology. 2004;66:112\u20137.","journal-title":"Oncology"},{"key":"3440_CR17","first-page":"2233","volume":"8","author":"A Bowman","year":"2002","unstructured":"Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res. 2002;8:2233\u20139.","journal-title":"Clin Cancer Res"},{"key":"3440_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ygyno.2009.01.012","volume":"113","author":"PA Argenta","year":"2009","unstructured":"Argenta PA, Thomas SG, Judson PL, Downs LS, Geller MA, Carson LF, et al. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol. 2009;113:205\u20139. doi:\n10.1016\/j.ygyno.2009.01.012\n\n.","journal-title":"Gynecol Oncol"},{"key":"3440_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ygyno.2006.10.053","volume":"105","author":"U Wagner","year":"2007","unstructured":"Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, L\u00fcck HJ, et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy-a phase II trial of the AGO ovarian cancer study group (AGO-OVAR 2.6). Gynecol Oncol. 2007;105:132\u20137. doi:\n10.1016\/j.ygyno.2006.10.053\n\n.","journal-title":"Gynecol Oncol"},{"key":"3440_CR20","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ygyno.2003.08.021","volume":"91","author":"M Carmen del","year":"2003","unstructured":"del Carmen M, Fuller A, Matulonis U, Horick N, Goodman A, Duska L, et al. Phase II trial of anastrozole in women with asymptomatic m\u00fcllerian cancer. Gyne Oncol. 2003;91:596\u2013602.","journal-title":"Gyne Oncol"},{"key":"3440_CR21","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ygyno.2010.08.002","volume":"119","author":"J Hurteau","year":"2010","unstructured":"Hurteau J, Brady M, Darcy K, McGuire W, Edmonds P, Pearl M, et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum\/taxane chemotherapy. Gyne Oncol. 2010;119:444\u201350.","journal-title":"Gyne Oncol"},{"key":"3440_CR22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1525-1438.1995.05040301.x","volume":"5","author":"J Velden Van Der","year":"1995","unstructured":"Van Der Velden J, Gitsch G, Wain GV, Friedlander ML, Hacker NF. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 1995;5:301\u20135.","journal-title":"Int J Gynecol Cancer"},{"key":"3440_CR23","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1002\/cncr.24508","volume":"115","author":"RK Hernandez","year":"2009","unstructured":"Hernandez RK, S\u00f8rensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer. 2009;115:4442\u20139. doi:\n10.1002\/cncr.24508\n\n.","journal-title":"Cancer"},{"key":"3440_CR24","unstructured":"Beale P, O\u2019Connell R, Sjoquist K, Martyn J, Cannon D, Bonaventura T, et al. PARAGON- an ANZGOG phase 2 study of anastrazole in asymptomatic women with estrogen (ER)\/ progesterone (PR) positive ovarian cancer with a CA125 progression after first line treatment. COSA. 2015;"},{"key":"3440_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/jcp.53.3.201","volume":"53","author":"HC Doorn van","year":"2000","unstructured":"van Doorn HC, Burger CW, van der Valk P, Bonfrer HMG. Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses. [article]. J Clin Pathol March. 2000;53:201\u20135. doi:\n10.1136\/jcp.53.3.201\n\n.","journal-title":"J Clin Pathol March"},{"key":"3440_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/annonc\/mdv516","volume":"27","author":"S Banerjee","year":"2016","unstructured":"Banerjee S, Kilburn L, Bowen R, Tovey H, Hall M, Kaye S, et al. Principal results of the cancer of the ovary abiraterone trial (CORAL): a phase II study of abiraterone in patients with recurrent epithelial ovarian cancer. Ann Oncol. 2016;27:1\u201336.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3440-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T10:57:39Z","timestamp":1498820259000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3440-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3440"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3440-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,30]]},"article-number":"456"}}